FDA staff said their review of research found insufficient evidence to support semax’s use for the conditions in question.
No event time was recorded for this claim — the text gave nothing to anchor it to, and a guessed date would be worse than none.
Standing
lens: Evidence-weighted Structural
No belief has been computed for this claim under Structural yet.
What bears on it
Nothing supports or challenges this claim yet — untested, which is not the same as refuted.
Voices
No asserter is recorded for this claim.
Sources
No source is recorded on this claim directly. It entered the record through FDA advisory panel narrowly rejects compounding of one peptide, backs two others .
Origin: extracted from FDA advisory panel narrowly rejects compounding of one peptide, backs two others · 2026-09-11 07:34